IDT Australia Director Geoffrey Sam Increases Indirect Shareholding

An update from IDT Australia Limited ( (AU:IDT) ) is now available.

IDT Australia Limited has reported a change in the interests of director Geoffrey Sam, who has increased his indirect holding in the company through family-related entities. The transactions, conducted via on-market trades on 30 April 2026 at prices of $0.041 and $0.040 per share, resulted in Sam’s indirect shareholding rising to 1,791,864 fully paid ordinary shares, while his direct holding remains unchanged.

The move signals a vote of confidence by the director in IDT Australia’s prospects, with the additional investment modestly increasing board-aligned ownership in the company. While the disclosure is primarily regulatory in nature, the expanded stake may be viewed positively by shareholders who often interpret director share purchases as an indication of alignment with investor interests and belief in future value creation.

More about IDT Australia Limited

IDT Australia Limited is an Australian pharmaceutical company that specializes in the development and manufacturing of active pharmaceutical ingredients and finished dose products. The company operates as a contract manufacturer for local and international clients, with a focus on regulated markets that require high-quality, compliant production capabilities.

Average Trading Volume: 188,921

Technical Sentiment Signal: Sell

Current Market Cap: A$16.45M

Find detailed analytics on IDT stock on TipRanks’ Stock Analysis page.